8.17

1.11% 0.09

Kyverna Therapeutics Inc (KYTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$8.08

Offen:

$8.1

24-Stunden-Volumen:

579.85K

Relative Volume:

0.57

Marktkapitalisierung:

$505.26M

Einnahmen:

Nettoeinkommen (Verlust:

$-156.40M

KGV:

-2.4909

EPS:

-3.2799

Netto-Cashflow:

$-151.53M

1W Leistung:

+2.64%

1M Leistung:

+2.90%

6M Leistung:

+12.53%

1J Leistung:

+130.79%

1-Tages-Spanne:

$7.80

$8.29

1-Wochen-Bereich:

$7.78

$8.6647

52-Wochen-Spanne:

$3.27

$13.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Firmenname

Kyverna Therapeutics Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

(510) 626-8331

Adresse

5980 HORTON STREET, EMERYVILLE

Mitarbeiter

129

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

KYTX's Discussions on Twitter

Compare KYTX vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KYTX Kyverna Therapeutics Inc	8.17	497.84M	0	-156.40M	-151.53M	-3.2799
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-20	Eingeleitet	William Blair	Outperform
2025-05-27	Hochstufung	H.C. Wainwright	Neutral → Buy
2024-10-10	Eingeleitet	UBS	Buy
2024-10-09	Eingeleitet	Rodman & Renshaw	Buy
2024-07-03	Eingeleitet	H.C. Wainwright	Neutral
2024-03-04	Eingeleitet	JP Morgan	Overweight
2024-03-04	Eingeleitet	Leerink Partners	Outperform
2024-03-04	Eingeleitet	Morgan Stanley	Overweight
2024-03-04	Eingeleitet	Wells Fargo	Overweight

Alle ansehen

Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten

Aug 14, 2026

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat

Aug 14, 2026

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan

Aug 14, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Aug 13, 2026

KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits

Aug 13, 2026

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 12, 2026

Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat

Aug 12, 2026

Aug 11, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Aug 11, 2026

Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade

Aug 11, 2026

Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times

Aug 11, 2026

KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView

Aug 11, 2026

Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan

Aug 11, 2026

FDA designation puts Kyverna’s one-dose cell therapy in focus for progressive MS - Stock Titan

Aug 11, 2026

Aug 09, 2026

Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 09, 2026

Aug 07, 2026

Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView

Aug 07, 2026